{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:06:51Z","timestamp":1788527211677,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaip.2018.12.011","type":"journal-article","created":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T08:59:23Z","timestamp":1551603563000},"page":"776-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hematopoietic Stem Cell Transplantation Beyond Severe Combined Immunodeficiency: Seeking a Cure for Primary Immunodeficiency"],"prefix":"10.1016","volume":"7","author":[{"given":"Richard","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.12.011_bib1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.12.011_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/bmt.2009.258","article-title":"Viral disease prevention after hematopoietic cell transplantation","volume":"44","author":"Zaia","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pbc.24847","article-title":"Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients","volume":"61","author":"Science","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaip.2018.12.011_bib5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.12.011_bib6","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib7","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood-2012-03-417758","article-title":"Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders","volume":"120","author":"Horan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib8","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2013-02-482547","article-title":"High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis","volume":"122","author":"Furst","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bbmt.2010.08.011","article-title":"Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities","volume":"16","author":"Barker","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/bmt.2009.137","article-title":"Unrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study","volume":"45","author":"Frangoul","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.2011.08735.x","article-title":"Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan","volume":"154","author":"Morio","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbmt.2013.11.005","article-title":"Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies","volume":"20","author":"Lane","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12400","article-title":"The current role of T cell depletion in paediatric stem cell transplantation","volume":"162","author":"Booth","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12810","article-title":"Transplantation of CD3\/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia","volume":"165","author":"Lang","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbmt.2016.02.001","article-title":"Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders","volume":"22","author":"Klein","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib16","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.bbmt.2015.07.008","article-title":"Single-center experience of unrelated and haploidentical stem cell transplantation with TCR\u03b1\u03b2 and CD19 depletion in children with primary immunodeficiency syndromes","volume":"21","author":"Balashov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","article-title":"T-cell receptor \u03b1\u03b2+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency","volume":"141","author":"Shah","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.jaip.2018.12.011_bib18","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bmt.2015.87","article-title":"Improved immune recovery after transplantation of TCR\u03b1\u03b2\/CD19-depleted allografts from haploidentical donors in pediatric patients","volume":"50","author":"Lang","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.08.019","article-title":"CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: a preliminary study","volume":"135","author":"Touzot","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbmt.2007.09.015","article-title":"Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation","volume":"14","author":"Bartelink","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation","volume":"15","author":"Bartelink","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbmt.2011.11.025","article-title":"Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling","volume":"18","author":"Lee","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00277-014-2196-8","article-title":"Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia","volume":"94","author":"Boztug","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib24","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/bmt.2015.171","article-title":"Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases","volume":"50","author":"Slatter","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib25","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.bbmt.2017.06.002","article-title":"Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders","volume":"23","author":"Burroughs","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib26","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1182\/blood-2010-10-312082","article-title":"Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience","volume":"117","author":"Slatter","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib27","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","article-title":"Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial","volume":"20","author":"Burroughs","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbmt.2017.11.009","article-title":"Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience","volume":"24","author":"Slatter","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"Gungor","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.12.011_bib30","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2016.02.022","article-title":"Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency","volume":"138","author":"Al-Herz","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib31","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","article-title":"Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation","volume":"116","author":"Marsh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaci.2016.01.053","article-title":"Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen","volume":"138","author":"Rao","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib33","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2015-12-684498","article-title":"The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis","volume":"127","author":"Hartz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbmt.2014.10.010","article-title":"Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases","volume":"21","author":"Haines","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kroger","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaip.2018.12.011_bib36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2007.01.076","article-title":"The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants","volume":"13","author":"Shah","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.2012.09048.x","article-title":"T\u00a0cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients","volume":"157","author":"Geyer","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib38","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib39","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bbmt.2015.04.009","volume":"21","author":"Marsh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib40","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib41","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaci.2013.09.044","article-title":"Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience","volume":"133","author":"Shearer","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib42","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2014.11.029","article-title":"Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency","volume":"135","author":"Wehr","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaci.2013.07.035","article-title":"Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation","volume":"133","author":"Arkwright","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00005792-200005000-00004","article-title":"Genetic, biochemical, and clinical features of chronic granulomatous disease","volume":"79","author":"Segal","year":"2000","journal-title":"Medicine"},{"key":"10.1016\/j.jaip.2018.12.011_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","article-title":"Chronic granulomatous disease. Report on a national registry of 368 patients","volume":"79","author":"Winkelstein","year":"2000","journal-title":"Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.jaip.2018.12.011_bib46","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1007\/s10875-007-9160-5","article-title":"Inflammatory manifestations in chronic granulomatous disease (CGD)","volume":"28","author":"Rosenzweig","year":"2008","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib47","doi-asserted-by":"crossref","first-page":"e5234","DOI":"10.1371\/journal.pone.0005234","article-title":"Chronic granulomatous disease: the European experience","volume":"4","author":"van den Berg","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.jaip.2018.12.011_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2007.09.008","article-title":"Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study","volume":"126","author":"Martire","year":"2008","journal-title":"Clinical Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib49","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2013.05.031","article-title":"Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation","volume":"132","author":"Cole","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10875-012-9758-0","article-title":"Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant","volume":"33","author":"Cole","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib51","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaip.2018.12.011_bib52","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib53","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood-2002-02-0583","article-title":"Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000","volume":"100","author":"Seger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib54","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbmt.2012.11.619","article-title":"Outcomes of hematopoietic stem cell transplantation in primary immunodeficiency: a report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry","volume":"19","author":"Mitchell","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib55","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.bbmt.2016.08.013","article-title":"A\u00a0single-center experience comparing alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning with myeloablative busulfan, cyclophosphamide, and antithymocyte globulin for chronic granulomatous disease","volume":"22","author":"Khandelwal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib56","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","article-title":"Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience","volume":"128","author":"Morillo-Gutierrez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib57","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.bbmt.2018.03.029","article-title":"High incidence of autoimmune disease after hematopoietic stem cell transplantation for chronic granulomatous disease","volume":"24","author":"Yanir","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Pt 1","key":"10.1016\/j.jaip.2018.12.011_bib58","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3476(05)82002-5","article-title":"A\u00a0multi-institutional survey of the Wiskott-Aldrich syndrome","volume":"125","author":"Sullivan","year":"1994","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2018.12.011_bib59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2003-05-1480","article-title":"Clinical course of patients with WASP gene mutations","volume":"103","author":"Imai","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib60","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1586\/1744666X.2015.1062366","article-title":"Current and emerging treatment options for Wiskott-Aldrich syndrome","volume":"11","author":"Worth","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2008.03.009","article-title":"Immunodeficiency-associated lymphomas","volume":"22","author":"Tran","year":"2008","journal-title":"Blood Rev"},{"issue":"Suppl","key":"10.1016\/j.jaip.2018.12.011_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2008.10.007","article-title":"Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment","volume":"15","author":"Ochs","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib63","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/bmt.2012.31","article-title":"Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome","volume":"47","author":"Shin","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib64","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2016.158808","article-title":"A\u00a0risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome","volume":"102","author":"Shekhovtsova","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2018.12.011_bib65","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","article-title":"Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation","volume":"111","author":"Ozsahin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib66","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.bmt.1705512","article-title":"Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation","volume":"38","author":"Pai","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib67","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.bbmt.2018.03.006","article-title":"A\u00a0conditioning regimen with plerixafor is safe and improves the outcome of TCR\u03b1\u03b2+ and CD19+ cell-depleted stem cell transplantation in patients with Wiskott-Aldrich syndrome","volume":"24","author":"Balashov","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib68","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.bbmt.2017.11.019","article-title":"Outcomes after allogeneic transplant in patients with Wiskott-Aldrich syndrome","volume":"24","author":"Ngwube","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib69","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/asheducation-2013.1.605","article-title":"Hemophagocytic lymphohistiocytosis: pathogenesis and treatment","volume":"2013","author":"Janka","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaip.2018.12.011_bib70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjh.12138","article-title":"Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis","volume":"160","author":"Lehmberg","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib71","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10875-017-0443-1","article-title":"Effective immunological guidance of genetic analyses including exome sequencing in patients evaluated for hemophagocytic lymphohistiocytosis","volume":"37","author":"Ammann","year":"2017","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13462","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents","volume":"170","author":"Lehmberg","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib73","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaip.2018.12.011_bib74","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jpeds.2013.06.053","article-title":"Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment","volume":"163","author":"Chandrakasan","year":"2013","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2018.12.011_bib75","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2012-10-463166","article-title":"The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2","volume":"121","author":"Jessen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2010-06-284935","article-title":"X-linked lymphoproliferative disease due to SAP\/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease","volume":"117","author":"Booth","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib77","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2010-07-298372","article-title":"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency)","volume":"117","author":"Pachlopnik Schmid","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib78","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib79","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib80","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2141.2007.06922.x","article-title":"Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis","volume":"140","author":"Horne","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib81","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1177\/0883073808319073","article-title":"Central nervous system involvement in Turkish children with primary hemophagocytic lymphohistiocytosis","volume":"23","author":"Gurgey","year":"2008","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.jaip.2018.12.011_bib82","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15274","article-title":"How I treat primary haemophagocytic lymphohistiocytosis","volume":"182","author":"Marsh","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaip.2018.12.011_bib84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","article-title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","volume":"132","author":"Chinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib85","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2005-05-1819","article-title":"Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis","volume":"107","author":"Cooper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib86","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.bbmt.2018.01.022","article-title":"Outcomes of children with hemophagocytic lymphohistiocytosis given allogeneic hematopoietic stem cell transplantation in Italy","volume":"24","author":"Messina","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib87","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.bbmt.2013.09.001","article-title":"An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis","volume":"19","author":"Marsh","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3324\/haematol.2013.094730","article-title":"Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis","volume":"99","author":"Lehmberg","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2018.12.011_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11940-017-0439-4","article-title":"How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis?","volume":"19","author":"Horne","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.jaip.2018.12.011_bib90","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bbmt.2017.02.011","article-title":"Incidence and outcomes of central nervous system hemophagocytic lymphohistiocytosis relapse after reduced-intensity conditioning hematopoietic stem cell transplantation","volume":"23","author":"Lounder","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib92","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaci.2011.07.055","article-title":"Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency","volume":"128","author":"Rizzi","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib93","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.md.0000100046.06009.b0","article-title":"The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients","volume":"82","author":"Winkelstein","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.jaip.2018.12.011_bib94","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood-2003-06-2014","article-title":"Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002","volume":"103","author":"Gennery","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib95","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/petr.12538","article-title":"Hematopoietic stem cell transplant for hyper-IgM syndrome due to CD40L defects: a single-center experience","volume":"19","author":"Al-Saud","year":"2015","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib96","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaci.2015.02.020","article-title":"Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan","volume":"136","author":"Mitsui-Sekinaka","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib97","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaci.2016.07.039","article-title":"Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation","volume":"139","author":"de la Morena","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib98","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2010.08216.x","article-title":"Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy","volume":"150","author":"Rosenberg","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib99","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2015-02-628859","article-title":"Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation","volume":"126","author":"Fioredda","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaci.2014.12.1945","article-title":"The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency","volume":"136","author":"Engelhardt","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib101","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-014-0126-0","article-title":"DOCK8 deficiency: clinical and immunological phenotype and treatment options\u2014a review of 136 patients","volume":"35","author":"Aydin","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib102","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaip.2018.10.035","article-title":"Hematopoietic stem cell transplantation as treatment for patients with DOCK8 deficiency","volume":"7","author":"Aydin","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.12.011_bib103","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00005792-200111000-00006","article-title":"MHC class II deficiency: a disease of gene regulation","volume":"80","author":"Villard","year":"2001","journal-title":"Medicine"},{"key":"10.1016\/j.jaip.2018.12.011_bib104","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.bbmt.2010.01.002","article-title":"Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency","volume":"16","author":"Al-Mousa","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/bmt.2012.140","article-title":"Alternative donor SCT for the treatment of MHC class II deficiency","volume":"48","author":"Small","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib106","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/ACI.0000000000000214","article-title":"The immunological and genetic basis of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome","volume":"15","author":"Bin Dhuban","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib107","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","article-title":"Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study","volume":"141","author":"Barzaghi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10875-015-0218-5","article-title":"Immune dysregulation syndromes (IPEX, CD27 deficiency, and others): always doomed from the start?","volume":"36","author":"Seidel","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib109","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaci.2016.01.045","article-title":"Hematopoietic stem cell transplantation for CTLA4 deficiency","volume":"138","author":"Slatter","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib111","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaci.2016.08.039","article-title":"Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant","volume":"139","author":"Chandrakasan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib112","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaip.2017.06.041","article-title":"Autosomal dominant hyper-IgE syndrome in the USIDNET registry","volume":"6","author":"Gernez","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.12.011_bib113","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood-2013-11-538686","article-title":"XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.12.011_bib114","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/pai.12051","article-title":"The role of hematopoietic stem cell transplantation in SP110 associated veno-occlusive disease with immunodeficiency syndrome","volume":"24","author":"Ganaiem","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib115","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.011_bib116","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.bbmt.2012.03.003","article-title":"Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism","volume":"18","author":"Eapen","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib117","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/pbc.20531","article-title":"Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation","volume":"47","author":"Hoffmeister","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaip.2018.12.011_bib118","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MD.0b013e31812f864d","article-title":"A\u00a0prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation","volume":"86","author":"Leung","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.jaip.2018.12.011_bib119","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/bmt.2011.78","article-title":"Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence","volume":"47","author":"Borgmann-Staudt","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bjh.13497","article-title":"Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan","volume":"170","author":"Panasiuk","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2018.12.011_bib121","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/pbc.26219","article-title":"Incident cancers and late mortality in Australian children treated by allogeneic stem cell transplantation for non-malignant diseases","volume":"64","author":"Nelson","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaip.2018.12.011_bib122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbmt.2016.10.004","volume":"23","author":"Dietz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2018.12.011_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26600","article-title":"Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981830833X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981830833X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:19:30Z","timestamp":1761974370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321981830833X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S221321981830833X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.12.011","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Stem Cell Transplantation Beyond Severe Combined Immunodeficiency: Seeking a Cure for Primary Immunodeficiency","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}